Research Studies

This page provides people living with mental illness, their families, and mental health researchers with an opportunity to connect in mental health research studies.

NAMI-NYC does not endorse any study on this page.  Information is provided purely as a public service.

A group wishing to post on this page must submit their current IRB approval for the study, in addition to a written synopsis of your study answering the following:

  • A title – see studies below for examples
  • A brief description of why you’re performing the study, and what people will be doing.
  • Is the study therapeutic (offering treatment) or non-therapeutic?
  • Is the study funded?  If yes, provide source of all funding; e.g., non-profit organization, governmental agency, or for-profit corporation including any ties to the pharmaceutical industry.
  • Who will be conducting the study?  E.g. non-profit, government, hospital, or for-profit corporation, including any companies that run clinical trials.
  • Will subjects be paid?  Include amount and payment schedule.
  • A person to contact, and a website for more general information.
  • When does the post expire? E.g. 6 months, one year, other.

Current Studies

November 2018: Analyzing voice samples for health characteristics

Depression affects up to 20% of the population in a given year. We’re asking patients to provide a short speech sample and complete a survey (e.g. a modified PHQ-9 score) so we can determine whether an individual is depressed from acoustic and linguistic features. By being a part of the study as a patient or a control, you will help us build better algorithms to detect depression symptoms from voice samples.

Patients can participate on laptops, tablets, or mobile devices: https://mha.neurolex.ai. You can also try a demo: http://collect.neurolex.ai.

By analyzing short voice samples for unique health characteristics, our technology discovers specific speech variations that indicate different health abnormalities earlier than previously possible. These new, proprietary tools give patients and providers greater visibility into their overall well-being, enabling early action to prevent symptoms from worsening.

At NeuroLex we are empowering patients with tools to measure their overall health through collecting and analyzing speech samples. By fingerprinting health abnormalities early, we equip patients and physicians with insight to prevent symptoms from worsening. In this way, we strive to be the world’s leading platform company to advance linguistics as a tool to characterize psychiatric and neurological health conditions.

Is the study therapeutic (offering treatment)? Non-therapeutic

Is the study funded? This research study is funded internally by NeuroLex Laboratories, a for-profit company. There are no disclosed ties to the pharmaceutical industry. We are actively pursuing government grants like SBIRs to further our work.

Who will be conducting the study? NeuroLex is conducting the study in close collaboration with several academic partners.

Go to NeuroLex to read more about the company and the technology.

October 2018: Exploring early interventions for people at risk of psychosis

This study is looking at whether an investigational medication called BI 409306 is safe and effective in reducing the early symptoms of psychosis. The goal of this study is to increase treatment options available for people experiencing the early symptoms of psychosis.

Participants may be eligible for this study if they are:

  • 16-30 years old
  • Experiencing early symptoms of psychosis
  • Have not yet experienced a first episode of psychosis

If you have questions or would like more information, please refer to the trial website (https://1289-0032study.com)

September 2018: Tobacco Use Survey

This study is an anonymous online survey that looks at tobacco use by people who experience mental health conditions. The goal of this study is to give researchers more information about how many people in this population use tobacco, how many would like to quit using tobacco, and some of the important experiences and feelings involved. Collecting this information is very important to support future research in tobacco cessation.

Participants may be eligible for this study if they:

  • Are 18 years or older
  • Have been diagnosed with a mental health condition

Please select this link to access the survey: https://uofmississippi.qualtrics.com/jfe/form/SV_0cuRZjHQUM5BZLD

If you have questions about this study, you may contact the research team directly. Dr. Joshua Mann can be reached at jmann4@umc.edu.

September 2018: Treatments for Anxiety: Mindfulness vs. Escitalopram (TAME)

The purpose of this study is to compare the effects of Mindfulness-Based Stress Reduction (MBSR) with Escitalopram (Lexapro) for treating anxiety disorders, specifically social anxiety disorder, generalized anxiety disorder, panic disorder, and agoraphobia. Participants are randomized into two 8-week treatments: (1) MBSR and (2) escitalopram.

MBSR intervention will include a weekly 2.5 hour class for 8 weeks. The intervention will also include a 1-day (7 hours) retreat on a weekend at the end of the program. Participants will also be asked to engage in 45 minutes of practice at home on a daily basis, as well as informal practice assignments that instruct participants to bring mindfulness to current daily activities.

Participants will receive free treatment no matter which arm they are assigned to. They will need to come to our offices in Midtown East Manhattan for a 3-hour screening visit, a 1-hour baseline visit, and 5-6 study assessment visits. There will also be follow-up visits at 3 months and 6 months.

Participants will receive $20 per study visit, not including screening. If participants complete the study, they will receive $160. We can also reimburse up to $10 in transportation costs for each visit.

For more information, please call 1-888-44-WORRY or email anxietystudy@nyumc.org. This study is run by NYU Langone Health.

August 2018: Developing a smartphone app to help manage mood and stress

We are a behavioral health startup based in New York City.  We are currently developing a self-directed cognitive behavioral therapy app for iOS and Android devices to help individuals better manage their stress, anxiety, and mood.  The app consists of a six-week interactive curriculum written by clinical psychologists.  Through educational material and homework assignments, the app teaches users to differentiate between their thoughts and feelings, and to develop healthy self-care behaviors.

We are currently conducting a consumer-focused product research and are looking for participants to take part in a focus group which would give participants the opportunity to play around with the app and provide feedback.

Participation in our research consists of an in-person interview at a WeWork office in New York City during the month of September.  The interview will take no longer than 60 minutes and participants will be compensated.

To participate individuals must:

  • Be 18 years or older
  • Have a smartphone
  • Have, or have had private health insurance
  • And be interested in managing their mood, reducing stress, or increasing their happiness

To see if you qualify, please take this survey: https://digitalhealth1.typeform.com/to/XPSJBW.

For questions, email research.digital.health@gmail.com.

August 2018: After Early Intervention: Young People's Trajectories Following Discharge from Specialized Early Psychosis Services

To date, very little is known about client and family experiences following discharge from specialized first episode psychosis/early intervention programs (like OnTrack) or how to best support them. This study aims to better understand what happens after discharge from OnTrack, including in the areas of school or work involvement and access to/use of other mental health services.

Who Is Eligible: Any family member of a former OnTrack client who has been discharged at least one year prior to a scheduled interview is eligible. Former clients will be recruited for the project through the OnTrack sites at which they initially received services.

Study Activity & Time Involved: If interested, you would be asked to participate in an approximately 1.5 hour long oral interview by phone or in person. This is not a treatment study.

Compensation: You will be compensated $75 for your time.

Who to Contact: To ask any questions or get involved, please contact Dr. Jones directly at 773-639-8360 or by email at genevra@usf.edu.

August 2018: Bipolar I with Mania Symptoms

In this study, local doctors are evaluating an investigational drug that is being developed for the treatment of manic episodes. They want to compare the investigational drug to placebo, which looks like the investigational drug, but contains no active medication

The investigational drug is currently approved in Canada and the United States for the treatment of schizophrenia. It is also approved in the United States as an added treatment to antidepressants for major depressive disorder. It has not been approved anywhere to treat manic episodes related to bipolar disorder. The results of this study will help provide more information about the investigational drug and whether it could one day be used as a treatment for manic episodes.

Who is eligible to participate in this study? To pre-qualify for this study, you must:

  • Be 18 to 65 years of age
  • Have been diagnosed with bipolar I disorder
  • Be having symptoms of a manic episode

All study-related visits, tests, and drugs will be provided at no cost. In addition, reimbursement for study-related travel may be provided.

To see if you are eligible for this study, please click here: leapcurebipolardisorder.studies.leapcure.com

June 2018: Improving Cognition via Exercise in Schizophrenia

People with schizophrenia display a broad range of cognitive impairments that have been identified as major determinants of poor functioning and disability. The goal of the proposed study is to examine the impact of exercise training on cognition, daily functioning, and biomarkers of cognitive change in people with schizophrenia.

Description – Following a baseline research assessment, participants will be randomized to Aerobic Exercise (AE) training or Stretching & Toning (ST) exercise training.

Participants in both groups will take part in a 12-week, 3 times per week, 1-hour training program, in addition to their regular psychiatric and/or medical care.  Participants may continue to be treated by their current psychiatrist and/or other mental health clinicians during the study.  All training will be led by a trainer in a small group setting.  Research assessments will be administered at baseline, and after 6- and 12-weeks of training.  These include diagnostic, clinical and cognitive assessments (interviews, questionnaires, cognitive tasks); fitness assessments and physical activity monitoring; and providing urine and blood samples.

Additional information is available at: https://clinicaltrials.gov/ct2/show/NCT03270098?term=NCT03270098&rank=1

Is the study therapeutic? – Yes.

Is the study funded? – Yes, the study is funded by a federal grant from the National Institute of Mental Health, Bethesda, MD (NIMH, Grant # R01 MH 110623)

Would subject be paid? – Eligible participants may receive up to $260 for the completion of the study, in addition to reimbursement of travel expenses.

Contact Information – Interested participants should contact Dr. Luz Ospina, the study director, at luz.ospina@mssm.edu or call 212-659-8749.

May 2018: Seeking patients with major depressive disorder (MDD) between the ages of 18 and 65 to participate in a new depression research study

A Double-Blind, Placebo-Controlled Study of Brexpiprazole plus Ketamine in Treatment-Resistant Depression (TRD)

Montefiore Medical Center is seeking patients with major depressive disorder (MDD) between the ages of 18 and 65 to participate in a new depression research study.

Dr. Jonathan Alpert is conducting this research to assess if the combination of brexpiprazole and intranasal ketamine can safely and effectively treat depression symptoms when added to stable, ongoing antidepressant treatment.  Ketamine is approved by the U.S. Food and Drug Administration (FDA) to be used with other drugs for anesthesia and as a pain reliever during procedures.  However, ketamine is not approved by the FDA to treat depression.  Brexpiprazole (Rexulti) is approved by the U.S. Food and Drug Administration (FDA) as an add-on treatment to an antidepressant medication to treat adults with major depressive disorder (MDD).  Participants will receive either the active study medication (1/2 chance of receiving brexiprazole) plus 40 mg of ketamine administered intranasally ,  or placebo (1/2 chance of receiving placebo) plus 40 mg of ketamine administered intranasally.  Participants will be monitored by an experienced study physician.  The study requires 12 visits to our research clinic over a period of 5 to 8 weeks, depending on the length of the screening portion.

Participants will receive compensation for their time.  You will be paid $450 if you complete the study.  If you do not complete the study, you will be paid for each visit you complete.

Please contact Jennifer Alexander if you or someone you know is interested in learning more about this study.

Jennifer Alexander
929-429-5644
jealexan@montefiore.org

February 2018: Well-being among adult siblings of individuals with a mental/ developmental disability

The aim of this study is to measure well-being among non-disabled adult siblings of individuals with a mental disability. Previous research shows that some siblings have higher levels of well-being than others, based on different factors that are related to it, such as gender. I am interested to see if other factors are also related to well-being. As part of my Master’s in Clinical Psychology in England, I am conducting a study (thesis) and will be glad if you answer my online questionnaire. Participation takes approximately 5 minutes and is anonymous.

I am interested in the well-being of adult siblings of individuals with any mental or developmental disability. Further information can be found at the link below.

So ***if you are an adult sibling (18 years or older) and you are NOT diagnosed with ANY mental or developmental disability*** please take part in the survey by clicking here: https://aruspsych.eu.qualtrics.com/jfe/form/SV_5pPAA6ceRbEaotL

You can withdraw from the study at any stage by closing the browser. In case you have completed the study and still wish to withdraw, you will be asked to type a memorable code which will enable me to exclude you from the study. In such a case, please contact me via email noting your withdrawal.

Email: ronit.hadad@student.anglia.ac.uk

Participation will take approximately 5 minutes.

December 2017: Does your child struggle to stay organized?

Does your child struggle to stay organized?

Many children with conditions like Attention-Deficit/Hyperactivity Disorder (ADHD) struggle to stay organized, manage their time, and plan activities. Even when ADHD is being well treated, organizational problems can cause difficulties in school and create headaches at home.

Children in grades 3-5 (who have one main teacher) are being recruited for a therapeutic study on brain function at the NYU Child Study Center funded by the National Institute of Mental Health.

Children must show difficulty with organization, time management or planning.

The study will include

  • a brief no-cost assessment
  • two brain MRI scans at NYU
  • a no-cost weekly individualized treatment for 12 weeks

Participants will be compensated $75 for the initial evaluation and $75 for each of the two MRI scan sessions.

For more information, please contact us at (646) 754-5147 or csc.organizedkids@nyumc.org, or visit our website: bit.ly/organized-kids.

September 2017: First Episode Psychosis Research Study

The Schizophrenia Research Program at NYU Langone Health, is currently seeking individuals (ages 16-30) with a diagnosis of schizophrenia, schizotypal, or schizophreniform disorder who have not taken antipsychotic medication for at least 4 weeks to participate in our research study funded by the National Institute of Mental Health.

In our study, we are looking for an alternative treatment for individuals with early psychosis. We are trying to see if a single dose of an anticonvulsant medication may be able to quiet down a specific part of the brain.

The study involves:

  • Two study visits
  • Two brain imaging scans
  • One single dose of Keppra (an FDA approved anticonvulsant medication) or placebo.

If eligibility criteria are met, participants will receive $200 for the completion of the study in addition to reimbursement for travel. If you are interested in participating or want more information please call or text our study team at (917) 565-1581 or email us at GoffLab@nyumc.org.

August 2017: A qualitative study that explores the lived experience of trauma survivors who have experienced misdiagnosis

Announcing a research project exploring the experiences of individuals who report a history of exposure to trauma but in the past did not receive a diagnosis that reflected recognition of their trauma-related reactions.

If you have been exposed to a traumatic event (such as the loss of a loved one or domestic violence), sought help from a mental health practitioner, and were not accurately diagnosed for trauma reactions, please consider participating in this study. You will have the opportunity to share how being wrongly diagnosed impacted you. Taking part in this study may lead to greater understanding of experiences, which could help develop future policies and programs to assist in accurately diagnosing individuals exposed to trauma and inform appropriate services.

I am a social worker and doctoral candidate at Adelphi University working on this research as a requirement for my degree. If you take part in this study, we will arrange to meet at a day and time that is convenient for you. We will also arrange to meet in a public place, such as the Manhattan Center at Adelphi University or a different public location that you are comfortable with. Everything you share will be kept confidential. Participation will include three separate interviews, 60-90 minutes each, for a total of 4-5 hours. At the end of the last interview session, we will take 1-2 hours to review the transcripts.

Participants must be 18 years or older. There will be no compensation for your participation.

If you are interested in participating in this study, or if you have any questions and would like more information, please contact Lisa Henshaw, LCSW at Lhenshaw@adelphi.edu or call (516) 316-6845.

June 2017: Brain Imaging Study of Hearing Voices

We are seeking patients living with schizophrenia (ages 18-55) to participate in an imaging study investigating the mechanisms underlying auditory hallucinations in psychosis.

  • The study involves non-invasive MRI scans, computer tasks, and interviews at the New York State Psychiatric Institute, in New York City.
  • Earn up to $450 (partly depending on task performance) plus travel costs.
  • For more information, call 646-774-8137, or email bakerse@nyspi.columbia.edu.